Relay Therapeutics (RLAY) Liabilities and Shareholders Equity (2019 - 2026)

Relay Therapeutics (RLAY) has reported Liabilities and Shareholders Equity for 8 consecutive years, with $699.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 12.48% year-over-year to $699.6 million; the TTM figure through Mar 2026 stood at $2.7 billion (down 19.37% YoY), while the FY2025 annual figure was $621.3 million, down 28.69% from the prior year.
• Liabilities and Shareholders Equity advanced to $699.6 million in Q1 2026 per RLAY's latest filing, from $621.3 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.2 billion in Q3 2022 and bottomed at $621.3 million in Q4 2025.
• Historically, Liabilities and Shareholders Equity has averaged $870.2 million across 5 years, with a median of $871.3 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 176443.5% — and 2025, when it slipped 28.69%.
• Relay Therapeutics' Liabilities and Shareholders Equity stood at $1.1 billion in 2022, then slipped by 23.26% to $844.0 million in 2023, then grew by 3.24% to $871.3 million in 2024, then retreated by 28.69% to $621.3 million in 2025, then grew by 12.6% to $699.6 million in 2026.
• Business Quant data shows RLAY's Liabilities and Shareholders Equity at $699.6 million in Q1 2026, $621.3 million in Q4 2025, and $670.0 million in Q3 2025.